S
S

Sanofi


News

GSK lifts 2022 forecast again after stronger than expected quarter

By Natalie Grover Nov 2 (Reuters) - GSK GSK.L on Wednesday GSK GSK.L on Wednesday smashed analysts' estimates for third-quarter earnings, driven by higher sales of its blockbuster shingles vaccine, Shingrix. This quarter, Shingrix blew past expectations by generating sales of 760 million pounds ($872.86 million) compared to the GSK-compiled consensus of 685 million pounds.
B
G
P
S

French drugmaker Sanofi expects positive boost from currency markets in Q3

PARIS, Sept 28 (Reuters) - French drugmaker Sanofi SASY.PA said it expected a positive boost to its third-quarter business results from movements on the currency markets, helped by the strength of the U.S. dollar since Sanofi does much of its business in the United States. Sanofi said its preliminary estimate of currency impacts on its third-quarter 2022 sales was for a boost of approximately 10% to 11%, and for a lift of around 12% and 13% on its business earnings per share (EPS).
S

Financial Times - Aug 18

Aug 18 (Reuters) - The following are the top stories in the Financial Times. Reuters has not verified these stories and does not vouch for their accuracy. Headlines - Ofgem director quits in protest at changes to price cap calculation Link - Genesis CEO exits after crypto broker took hit from Three Arrows collapse Link - Sanofi drops experimental breast cancer drug after second trial fails Link - Jim Ratcliffe declares interest in buying Manchester United Link Overview - A board member of Ofgem
S

UK first to approve Omicron COVID shot with Moderna nod

* UK's JCVI backs using bivalent shot in autumn booster campaign * Moderna sees Australia, Canada, EU approvals soon By Natalie Grover LONDON, Aug 15 (Reuters) - Britain, the first country to approve a coronavirus vaccine in late 2020, has now also given the first green light to a variant-adapted shot that targets both the original and Omicron version of the virus.
A
G
P
S

European shares eke out gains at open as healthcare stocks rebound

(For a Reuters live blog on U.S., UK and European stock markets, click LIVE/ or type LIVE/ in a news window) Aug 12 (Reuters) - European shares eked out gains on Friday at the open after Sanofi and GSK led a rebound in healthcare stocks, with the main STOXX 600 index set for weekly gains. Sanofi SASY.PA rose 1.6% and GSK GSK.L added 3.0% after a heavy selloff in the previous session on growing worries about U.S.
S
E
F
U
G

UK Stocks-Factors to watch on Aug 12

Aug 12 (Reuters) - Britain's FTSE 100 .FTSE index is seen opening flat with futures .FFIc1 up 0.1% on Friday. * FLUTTER: Flutter FLTRF.I posted a 20% fall in first-half earnings but expects to finish the year ahead of 2021 excluding an expected final year of losses in its fast growing U.S. business. * 888 HOLDINGS: 888 Holdings Plc 888.L reported a fall in its interim profit, hurt by tightened UK online gambling safety measures and the cost-of-living crisis.
A
S
F
N
U

Haleon not a party to U.S. litigation focused on Zantac - spokesperson

By Natalie Grover LONDON, Aug 11 (Reuters) - Haleon - GSK's recently spun off consumer health unit - is not a party to U.S. litigation focused on the heartburn medicine Zantac, a spokesperson told Reuters on Thursday. "We have never marketed Zantac in any form in the U.S., as Haleon or as GSK consumer healthcare," the spokesperson said, responding to Reuters querying a near-20% decline in Haleon's share price this week.
G
P
S

Haleon not a party to U.S. litigation focused on Zantac - spokesperson

LONDON, Aug 11 (Reuters) - Haleon - GSK's recently spun off consumer health unit - is not a party to the U.S. litigation focused on the heartburn medicine Zantac, a spokesperson told Reuters on Thursday. "We have never marketed Zantac in any form in the U.S., as Haleon or as GSK consumer healthcare," the spokesperson said in response to queries about sharp declines in Haleon shares.
G
S

Wacker Chemie invests 100 million euros in mRNA factory

By Zuzanna Szymanska BERLIN, July 5 (Reuters) - Chemicals group Wacker Chemie WCHG.DE has commissioned construction firm Exyte to build a plant for mRNA components, a medical technology first widely used in COVID-19 vaccines, in an investment of 100 million euros ($102.97 million). Wacker said on Tuesday the German state would pay an annual fee to reserve about half of its capacity for its pandemic preparedness programme but declined to say if and how much the state had paid for the construction
I
P
S
W

Defensive stocks lead rebound in FTSE 100

(For a Reuters live blog on U.S., UK and European stock markets, click or type LIVE/ in a news window) * FTSE 100 and FTSE 250 snap 3-week losing streak * British retail sales dip in May * Consumer confidence in the UK hits record low * FTSE 100 up 2.7%, FTSE 250 adds 2.3% (Updates to close) By Boleslaw Lasocki June 24 (Reuters) - UK's FTSE 100 rose on Friday, lifted by defensive stocks at the end of a choppy week that saw investor anxiety over hawkish central banks, weak economic readings and h
S
U

Bridgewater's bearish bets on European stocks jump to $10.5 bln - Bloomberg News

June 23 (Reuters) - Bridgewater Associates has raised its short position on European stocks to $10.5 billion, nearly doubling from the previous week, according to a Bloomberg News report on Thursday, in a sign the hedge fund was increasingly bearish on equities in the continent. Bridgewater disclosed short bets against 28 companies that include individual wagers of more than $500 million against ASML Holding NV ASML.AS , TotalEnergies SE TTFE.PA , Sanofi SASY.PA and SAP SE SAPG.DE , according to
A
B
I
S
S
S
A
A
I

Bridgewater bets $6.7 billion against European stocks

By Carolina Mandl NEW YORK, June 16 (Reuters) - Bridgewater Associates has placed at least $6.7 billion in bets against European stocks, according to data group Breakout Point, in a sign that the hedge fund firm may be pessimistic about companies on the continent. Using Bridgewater's public disclosures, Breakout Point calculated that the Connecticut-based fund has bet against 21 European companies so far this week, in sectors ranging from finance to energy.
A
B
I
S
S
A
A
I

Bridgewater bets $6.7 billion against European stocks

By Carolina Mandl NEW YORK, June 16 (Reuters) - Bridgewater Associates has placed at least $6.7 billion in bets against European stocks, according to data group Breakout Point, in a sign that the hedge fund firm may be pessimistic about companies on the continent. Using Bridgewater's public disclosures, Breakout Point calculated that the Connecticut-based fund has bet against 21 European companies so far this week, in sectors ranging from finance to energy.
A
B
I
S
S
A
A
I

Sanofi targets Dupixent peak sales of over 13 bln euros

PARIS, March 29 (Reuters) - French healthcare group Sanofi SASY.PA , which lagged rivals in the race for COVID-19 vaccines, raised on Tuesday its peak sales target for eczema-treatment product Dupixent to more than 13 billion euros ($14.3 billion). "This new ambition does not include potential for additional sales ambition upgrade from chronic obstructive pulmonary disease (COPD), with pivotal readouts anticipated in 2023," Sanofi said in a statement.
G
R
S

Healthcare group Sanofi targets Dupixent peak sales of over 13 bln euros

PARIS, March 29 (Reuters) - French healthcare group Sanofi SASY.PA , which lagged rivals in the race for COVID-19 vaccines, raised on Tuesday its peak sales target for eczema-treatment product Dupixent to more than 13 billion euros ($14.3 billion). "This new ambition does not include potential for additional sales ambition upgrade from chronic obstructive pulmonary disease (COPD), with pivotal readouts anticipated in 2023," Sanofi said in a statement.
G
R
S

UK Stocks-Factors to watch on Feb 24

Feb 24 (Reuters) - Britain's FTSE 100 index .FTSE is seen opening lower on Thursday, with futures FFIc1 down 2.04%. * SANOFI-GSK: French drugmaker Sanofi SASY.PA and its British partner GlaxoSmithKline GSK.L are seeking regulatory approval for their COVID-19 vaccine to be used as a booster, as well as a standalone two-dose shot, after several setbacks.
A
B
B
C
D
D
G
H
I
L
S
S
W
R
U

British Business - Feb 24

Feb 24 (Reuters) - The following are the top stories on the business pages of British newspapers. Reuters has not verified these stories and does not vouch for their accuracy. The Times - Britain's official climate advisers have left the door open for the government to approve more North Sea oil and gas drilling, saying that the impact on the planet of new domestic production is "not clear-cut".
B
G
S

Financial Times - Feb 24

Feb 24 (Reuters) - The following are the top stories in the Financial Times. Reuters has not verified these stories and does not vouch for their accuracy. Headlines Sanofi and GSK to seek approval for delayed COVID-19 vaccine. Link UK should bring forward tax rises to fight inflation, IMF says. Link UK warned future exploration of North Sea risks undermining climate credibility.
G
S

Sanofi, GSK to seek approval for COVID vaccine candidate

* Seeking approval as primary vaccine regimen and booster dose * Full trial results expected to be published later this year * Two doses 100% effective against severe COVID-19 * Booster dose boosts neutralizing antibodies across platforms PARIS, Feb 23 (Reuters) - French drugmaker Sanofi SASY.PA and its British partner GlaxoSmithKline GSK.L are seeking regulatory approval for their COVID-19 vaccine to be used as a booster, as well as a standalone two-dose shot, after several setbacks.
A
G
P
S

European shares rebound from Monday sell-off as energy stocks, miners jump

(For a Reuters live blog on U.S., UK and European stock markets, click LIVE/ or type LIVE/ in a news window) * ING to quit French retail banking business * Sanofi's $1 bln Amunix buyout to add to drugmaker's pipeline * European chipmakers rise on Micron's quarterly beat * Bollore soars after $6.4 bln offer for African logistics assets (Updates to close) By Anisha Sircar and Shashank Nayar Dec 21 (Reuters) - European shares ended higher on Tuesday, recovering Monday's losses, with a jump in commo
A
B
I
M
N
P
S
A
B
R
E
F
U
G



Conditions

Popular Assets

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

We are using cookies to give you the best experience on our website. Read more or change your cookie settings.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.